Cancer Incidence, Mortality, and Surveillance

Cancer incidence, mortality, and surveillance is the measurement side of cancer epidemiology: the systematic counting of new cancer cases and cancer deaths in defined populations, and the registries and statistical methods used to track them over time. These metrics provide the denominator-aware picture of cancer burden that prevention, screening, and health-policy decisions all depend upon.

Definition

Cancer surveillance is the ongoing, systematic collection and analysis of data on cancer occurrence and outcomes — chiefly incidence (new cases) and mortality (deaths) — in defined populations, usually through population-based cancer registries, to describe and monitor the cancer burden.

Scope

The topic covers the core measures of cancer occurrence — incidence, mortality, prevalence, and survival — the population-based cancer registries that generate them, and the standardisation methods (such as age-standardisation) that make rates comparable across populations and time. It treats these as descriptive epidemiologic tools; it does not address the management of individual cancers.

Core questions

• How are cancer incidence and mortality rates defined, measured, and standardised for comparison?
• What is a population-based cancer registry and how does it produce reliable statistics?
• How do incidence and mortality trends differ, and what do divergences between them indicate?
• How are global cancer estimates produced when registry coverage is incomplete?

Key concepts

• Incidence rate
• Mortality rate
• Prevalence
• Survival and case fatality
• Age-standardised rate
• Population-based cancer registry
• Crude versus adjusted rates
• Incidence-to-mortality ratio

Mechanisms

Incidence counts new cancer diagnoses in a population over a period and is typically expressed as a rate per 100,000 person-years; mortality counts cancer deaths over the same denominator. Because cancer risk rises sharply with age, raw (crude) rates are confounded by a population's age structure, so rates are age-standardised to a reference population to permit valid comparison across regions and over time. Population-based registries capture all incident cases in a geographic area and, linked to vital statistics, yield incidence, mortality, prevalence, and survival. Where registry coverage is sparse, agencies such as the International Agency for Research on Cancer model national estimates (GLOBOCAN) by combining the best available local data with statistical methods, an approach refined across successive estimation cycles.

Clinical relevance

Surveillance statistics tell clinicians and planners which cancers are common, rising, or falling, and where survival is improving — information that frames discussions of risk and the rationale for screening and prevention programmes. The topic describes how cancer burden is measured at the population level and is for reference orientation; it does not direct the care of any individual patient.

Epidemiology

Global estimates for 2022 put the worldwide burden at roughly 20 million new cancer cases and nearly 10 million cancer deaths, with lung, breast, and colorectal cancers among the most common, though the leading cancers and their rates vary substantially by region, sex, and level of development. Trends measured by surveillance — such as declining rates for some cancers and rising rates for others — are themselves a primary object of study.

History

Systematic cancer registration developed through the twentieth century, with population-based registries spreading internationally and being coordinated by bodies such as the International Agency for Research on Cancer and the International Association of Cancer Registries. The GLOBOCAN series, together with national programmes, has produced periodic global estimates of incidence and mortality, while large collaborations such as the Global Burden of Disease study placed cancer within a comprehensive accounting of disease burden, allowing trends to be tracked over decades.

Key figures

• Freddie Bray
• Jacques Ferlay
• Isabelle Soerjomataram
• Ahmedin Jemal

Seminal works

• ferlay-2015
• bray-2018
• bray-2024

Frequently asked questions

Why are cancer rates age-standardised?

Because cancer risk increases strongly with age, populations with older age structures have higher crude rates regardless of true risk; age-standardising to a reference population removes this distortion so rates can be compared fairly across places and time.

What does a population-based cancer registry do?

It systematically records all new cancer cases occurring in a defined geographic population and, by linking to vital records, produces incidence, mortality, prevalence, and survival statistics that underpin surveillance and research.